Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best overall response of the combination of
dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.